Drug
IDRX-42 clinical trials
Also written Velzatinib, GSK6042981 and IDRX-42.
Keep track of what changes. Save the IDRX-42 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
GlaxoSmithKline (6) · IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses IDRX-42 is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingPhase 3GlaxoSmithKlineNCT07585266Written as Velzatinib
- A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibNot yet recruitingPhase 1GlaxoSmithKlineNCT07867171Written as Velzatinib
- A Study to Investigate the Effects of Impaired Hepatic Function on VelzatinibNot yet recruitingPhase 1GlaxoSmithKlineNCT07859735Written as Velzatinib
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyRecruitingPhase 3GlaxoSmithKlineNCT07218926Written as IDRX-42
- A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRecruitingPhase 2GlaxoSmithKlineNCT07689201Written as Velzatinib
- A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)Not yet recruitingPhase 2GlaxoSmithKlineNCT07843641Written as Velzatinib
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruitingPhase 1IDRX, Inc., a wholly owned subsidiary of GSK, LLCNCT05489237Written as IDRX-42
Given in every arm · 1 — IDRX-42 is usual care beside what is tested
Codes
What other systems call IDRX-42 · ClinicalTrials.gg INT002061
- MeSH (NLM) C000729878IDRX-42One source ClinicalTrials.gov
- UNII (FDA) Y6UHU32G5ZVELZATINIBConfirmed FDA, Wikidata
- Wikidata Q131926975IDRX-42Confirmed FDA, Wikidata
- DrugBank DB18087One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729878 | IDRX-42 | One source ClinicalTrials.gov |
| UNII (FDA) | Y6UHU32G5Z | VELZATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q131926975 | IDRX-42 | Confirmed FDA, Wikidata |
| DrugBank | DB18087 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.